Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Jan;6(1):10-1.
doi: 10.1038/ncponc1261. Epub 2008 Oct 28.

A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

Axel Grothey  1
Affiliations
Comparative Study

A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

Axel Grothey. Nat Clin Pract Oncol. 2009 Jan.

Abstract

Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. J Clin Oncol. 2007 Sep 20;25(27):4224-30 - PubMed
    1. J Clin Oncol. 2008 Apr 20;26(12):2013-9 - PubMed
    1. J Clin Oncol. 2008 Jul 20;26(21):3523-9 - PubMed
    1. J Clin Oncol. 2007 Sep 20;25(27):4217-23 - PubMed
    1. J Clin Oncol. 2008 Apr 20;26(12):2006-12 - PubMed

LinkOut - more resources